(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
@ $2.33
Issued: 14 Feb 2024 @ 09:30
Return: 103.00%
Previous signal: Feb 12 - 14:19
Previous signal:
Return: -6.99 %
Live Chart Being Loaded With Signals
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders...
Stats | |
---|---|
Today's Volume | 510 503 |
Average Volume | 3.87M |
Market Cap | 333.46M |
EPS | $0 ( 2024-05-09 ) |
Next earnings date | ( $-0.690 ) 2024-06-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.460 |
ATR14 | $0.0100 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-16 | Moore Matthew Richard | Buy | 320 000 | Stock Option (Right to Buy) |
2024-05-16 | Moore Matthew Richard | Buy | 0 | |
2024-04-12 | Subramaniam Somu | Sell | 695 339 | Common Stock |
2024-04-12 | Nsv Partners Iii Lp | Sell | 695 339 | Common Stock |
2024-04-02 | Krueger Christopher W | Sell | 1 651 | Common Stock |
INSIDER POWER |
---|
-0.10 |
Last 99 transactions |
Buy: 2 403 814 | Sell: 2 314 120 |
Volume Correlation
Ventyx Biosciences, Inc. Correlation
10 Most Positive Correlations | |
---|---|
SVRA | 0.94 |
SY | 0.936 |
IDCC | 0.93 |
NVCN | 0.929 |
OVID | 0.929 |
HURC | 0.926 |
OVLY | 0.919 |
GPACU | 0.919 |
VBOC | 0.918 |
BYNOU | 0.916 |
10 Most Negative Correlations | |
---|---|
NAKD | -0.93 |
PRPH | -0.91 |
ORPH | -0.903 |
CSSEP | -0.902 |
CHKEL | -0.902 |
PROC | -0.9 |
ALXO | -0.898 |
HCAQ | -0.897 |
SGLY | -0.896 |
TRIT | -0.895 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ventyx Biosciences, Inc. Correlation - Currency/Commodity
Ventyx Biosciences, Inc. Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-941 000 (0.00 %) |
EPS: | $-3.30 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-941 000 (0.00 %) |
EPS: | $-3.30 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-470 000 (0.00 %) |
EPS: | $-2.06 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-6.65 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators